Prognostic significance of circulating tumor cell measurement in the peripheral blood of patients with nasopharyngeal carcinoma

Gao, Tinghua; Mao, Jinxing; Huang, Jindu; Luo, Fengling; Lin, Lixiang; Lian, Yingni; Bin, Sanmei; Zhao, Lianghua; Li, Shuping

doi:10.1016/j.clinsp.2023.100179

Tinghua Gao

conceived the project and designed the experiment

performed the experiments, collected, and analyzed the data

wrote the manuscript

reviewed and approved the final manuscript

Department of Oncology, First People’s Hospital of Zhaoqing City, Zhaoqing, Guangdong, China

Jinxing Mao

performed the experiments, collected, and analyzed the data

wrote the manuscript

reviewed and approved the final manuscript

Department of Oncology, First People’s Hospital of Zhaoqing City, Zhaoqing, Guangdong, China

Jindu Huang

performed the experiments, collected, and analyzed the data

reviewed and approved the final manuscript

Department of Oncology, First People’s Hospital of Zhaoqing City, Zhaoqing, Guangdong, China

Fengling Luo

performed the experiments, collected, and analyzed the data

reviewed and approved the final manuscript

Department of Oncology, First People’s Hospital of Zhaoqing City, Zhaoqing, Guangdong, China

Lixiang Lin

performed the experiments, collected, and analyzed the data

reviewed and approved the final manuscript

Department of Oncology, First People’s Hospital of Zhaoqing City, Zhaoqing, Guangdong, China

Yingni Lian

performed the experiments, collected, and analyzed the data

reviewed and approved the final manuscript

Department of Oncology, First People’s Hospital of Zhaoqing City, Zhaoqing, Guangdong, China

Sanmei Bin

performed the experiments, collected, and analyzed the data

reviewed and approved the final manuscript

Department of Oncology, First People’s Hospital of Zhaoqing City, Zhaoqing, Guangdong, China

Lianghua Zhao

performed the experiments, collected, and analyzed the data

reviewed and approved the final manuscript

Department of Oncology, First People’s Hospital of Zhaoqing City, Zhaoqing, Guangdong, China

Shuping Li ^**Corresponding author. E-mail address:laolitz@163.com (S. Li).

conceived the project and designed the experiment

wrote the manuscript

reviewed and approved the final manuscript

Department of Oncology, First People’s Hospital of Zhaoqing City, Zhaoqing, Guangdong, China

https://orcid.org/0000-0002-5945-7369

*Corresponding author. E-mail address:laolitz@163.com (S. Li).

Conflicts of interest

The authors declare no conflicts of interest.

Figures (4)
Tables (3)

Thumbnail

Figure 1
Correlation between CTCs or MCTCs count and treatment. (A) The comparison of CTCs count between pre-treatment and post-treatment. (B) The comparison of MCTCs count between pre-treatment and post-treatment. CTC, circulating tumor cell; MCTC, mesenchymal circulating cell.

Thumbnail

Figure 2
Correlation between CTC number, MCTC number and TNM stage. (A) In the pre-treatment group, the CTC number had significant difference between stage III and stage IVa. (B)In the pre-treatment group, the MCTC number had significant difference between early stage III and stage II, stage IVa, stage IVb. (C) In post-treatment group, CTCs number of the patients with stage IVa were statistically lower than those who with stage III and stage IVb. (D) In post-treatment group, the MCTCs number had significant difference between stage III and stage IVa.

Thumbnail

Figure 4
The comparison of progression-free survival (PFS) and overall survival (OS) in NPC patients with different treatments. (A) Relationship between three different therapies and PFS rate. Number 1 represents chemoradiotherapy, number 2 represents chemoradiotherapy combined targeted therapy, and number 3 represents chemotherapy combined targeted therapy. Statistical log rank test found that the p-value in the difference between group 1 and 2 is0.350, group 2 and group 3 is 0.065, while group 1 and group 3 is 0.0001. (B) Relationship between the number of metastatic lesions and PFS rate. (C) Relationship between the change in number of CTC after treatment and PFS rate. (D) Relationship between the change in number of CTC after treatment and OS rate. N1: the CTC counts before treatment. N2: the CTC counts after treatment. N: the absolute value of the change in number of CTC after treatment.

Thumbnail

Figure 3
The comparison of progression-free survival (PFS) and overall survival (OS) in NPC patients by KaplanMeier curves. (A) Relationship between CTC count and PFS rate. (B) Relationship between CTC count and OS rate. (C) Relationship between MCTC number and PFS rate. (D) Relationship between MCTC number and OS rate.

Thumbnail

Table 1
Capture probe sequences for the EpCAM, CK8/18/19, vimentin, and Twist.

Thumbnail

Table 2
The detailed characteristics of 70 blood samples collected before treatments (Fisher’s exact test and Pearson chi-square test).

Thumbnail

Table 3
The detailed characteristics of 49 blood samples collected after treatments (Fisher’s exact test and Pearson Chi-Square test).

Gene name	Sequences (5´-3´)
EpCAM	5-TGGTGCTCGTTGATGAGTCA AGCCAGCTTTGAGCAAATGA-3´
CK8	5-CGTACCTTGTCTATGAAGGA ACTTGGTCTCCAGCATCTTG-3´
CK18	5-AGAAAGGACAGGACTCAGGC GAGTGGTGAAGCTCATGCTG-3´
CK19	5-CTGTAGGAAGTCATGGCGAG AAGTCATCTGCAGCCAGACG-3´
Vimentin	5-GAGCGAGAGTGGCAGAGGAC CTTTGTCGTTGGTTAGCTGG-3´
Twist	5-ACAATGACATCTAGGTCTCC CTGGTAGAGGAAGTCGATGT-3´

Variables	n(%)	CTCs		p	MCTCs		p
Variables	n(%)	Positive, n (%)	Negative, n (%)	p	Positive, n (%)	Negative, n (%)	p
All samples	70	65 (92.86)	5 (7.14)		52 (74.29)	18 (25.71)
Age (years)
Mean	52.00
SD	10.123
Range	23-79
Gender				0.724			0.225
Male	47 (67.14)	44 (93.62)	3 (6.38)		37 (78.78)	10 (21.28)
Female	23 (32.86)	21 (91.30)	2 (8.70)		15 (65.22)	8 (34.78)
Smoking				0.362			0.066
No	32 (45.71)	30 (93.75)	2 (6.25)		27 (84.38)	5 (15.63)
Yes	38 (54.29)	35 (92.11)	3 (7.89)		25 (65.79)	13 (34.21)
TNM stage				0.798			0.520
I	1 (1.43)	1 (100.00)	0 (0.00)		0 (0.00)	1 (100.00)
II	6 (8.57)	5 (83.33)	1 (16.67)		5 (83.33)	1 (16.67)
III	28 (40.00)	27 (96.43)	1 (3.57)		21 (75.00)	7 (25.00)
IVa	26 (37.14)	24 (92.31)	2 (7.69)		19 (73.08)	7 (26.92)
IVb	9 (12.86)	8 (88.89)	1 (11.11)		7 (77.78)	2 (22.22)
Distant metastasis				0.797			0.620
Yes	9 (12.86)	7 (77.78)	2 (22.22)		8 (88.89)	1 (11.11)
No	61 (87.14)	45 (73.77)	16 (26.23)		57 (93.44)	4 (6.56)
Lymph node metastasis				0.623			0.097
Yes	67 (95.71)	62 (92.54)	5 (7.46)		51(76.12)	16 (23.88)
No	3 (4.29)	3 (100.00)	0 (0.00)		1 (33.33)	2 (66.67)

Variables	n(%)	CTCs		p	MCTCs		p
Variables	n(%)	Positive, n (%)	Negative, n (%)	p	Positive, n (%)	Negative, n (%)	p
All samples	49	42 (85.71)	7 (14.29)		33 (67.35)	16 (32.65)
Age (years)
Mean	50.00
SD	9.112
Range	35-69
Gender				0.136			0.071
Male	33 (67.35)	30 (90.91)	3 (9.09)		25 (75.76)	8 (24.24)
Female	16 (32.65)	12 (75.00)	4 (25.00)		8 (50.00)	8 (50.00)
Smoking				0.663			0.253
No	28 (57.14)	24 (85.71)	4 (14.29)		17 (60.71)	11 (39.29)
Yes	21 (42.86)	18 (85.71)	3 (14.29)		16 (76.19)	5 (23.81)
TNM stage				0.243			0.280
I	0 (0.00)	0 (0.00)	0 (0.00)		0 (0.00)	0 (0.00)
II	1 (2.04)	1 (100.00)	0 (0.00)		1 (100.00)	0 (0.00)
III	14 (28.57)	13 (92.86)	1 (7.14)		12 (85.71)	2 (14.29)
IVa	25 (51.02)	19 (76.00)	6 (24.00)		15 (60.00)	10 (40.00)
IVb	9 (18.37)	9 (100.00)	0 (0.00)		5 (55.56)	4 (44.44)
Distant metastasis				0.175			0.404
Yes	9 (18.37)	9 (100.00)	0 (0.00)		5 (55.56)	4 (44.44)
No	40 (81.63)	33	7		28 (70.00)	12 (30.00)
Lymph node metastasis				0.680			0.482
Yes	48 (97.96)	41 (85.42)	7 (14.58)		32 (66.67)	16 (33.33)
No	1 (2.04)	1 (100.00)	0 (0.00)		1 (100.00)	0 (0.00)

[1] *Corresponding author. E-mail address:laolitz@163.com (S. Li).

Brasil

Brasil

Prognostic significance of circulating tumor cell measurement in the peripheral blood of patients with nasopharyngeal carcinoma

Abstract

Objective:

Patients and methods:

Results:

Conclusion:

HIGHLIGHTS